Although the implications of PTEN loss and response to these treatments in the context of prostate cancer is yet to be evaluated, preclinical and clinical data from other cancer types are beginning to reveal that PTEN loss may desensitize patients to immunotherapy [360,368,369,370,371]. The gene discussed is PTEN; the disease is prostate carcinoma.